key: cord-0968500-t5owxikr
authors: Cavalli, Giulio; Dagna, Lorenzo
title: Anakinra for COVID‐19: how to interpret elevations in serum liver enzymes
date: 2020-09-22
journal: Arthritis Rheumatol
DOI: 10.1002/art.41525
sha: c8c83a4391e32006173d44edf62460b8408cd597
doc_id: 968500
cord_uid: t5owxikr

We read with interest the study by Navarro‐Millàn and colleagues on the use of anakinra in severe COVID‐19 patients with acute respiratory insufficiency and hyper‐inflammation (1). The Authors tried to identify the clinical phenotype that is most likely to benefit from anakinra treatment, in order to maximize utility and not to expose patients to unnecessary risks related to immunosuppression.

This article is protected by copyright. All rights reserved

We read with interest the study by Navarro-Millàn and colleagues on the use of anakinra in severe COVID-19 patients with acute respiratory insufficiency and hyper-inflammation (1) . The Authors tried to identify the clinical phenotype that is most likely to benefit from anakinra treatment, in order to maximize utility and not to expose patients to unnecessary risks related to immunosuppression.

Indeed, administration of anakinra to 11 patients yielded overall promising results, although the lack of a control group and prior administration of high-dose corticosteroids in 8 patients limit interpretation of findings. However, the Authors state that in previous studies of anakinra in COVID-19, severe respiratory failure was not a requisite for treatment initiation. This statement is incorrect, as a previous cohort study from our group in Milan, Italy, had remarkably similar eligibility criteria for anakinra administration. Specifically, all patients had hyper-inflammation defined as elevated ferritin and/or CRP, and acute respiratory distress syndrome requiring non-invasive ventilation (2) . Outcome measures were also similar, as was the ultimate aim to avoid mechanical ventilation.

Similarities between these studies help interpreting another finding of Navarro-Millàn and colleagues, that is, elevation in serum liver transaminases in patients receiving anakinra. Both the study by Navarro-Millàn and ours reported this finding, which led to tapering or discontinuation of anakinra in some patients. However, our study also included a control population of patients who, despite not receiving anakinra, exhibited similar elevations in serum liver enzymes (2) . This led us to hypothesize that elevations in serum liver enzymes reflect underlying diseases severity, rather than treatment toxicity. Elevation in serum liver enzymes is uncommon in patients receiving anakinra for approved indications. Conversely, it is a hallmark of both viral infections and macrophage activation syndrome, a condition sharing similarities with the hyper-inflammatory response observed in some COVID-19 patients and commonly treated with high-dose anakinra (3, 4) . Whether anakinra should be discontinued in patients with COVID-19 and elevated liver enzymes remains thereby debatable.

Albeit perceived as the clinically responsible choice, discontinuation of anakinra in these patients may actually give way to a detrimental hyper-inflammatory, of which elevated liver enzymes are not but an accompanying feature.

Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series. Arthritis & rheumatoloy

blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis

Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative